EirGenix Inc. (TPE:6589)
Taiwan
· Delayed Price · Currency is TWD 47.65
+1.55 (3.36%)
At close: Apr 28, 2026
EirGenix Revenue
In the year 2025, EirGenix had annual revenue of 1.01B TWD, down -0.38%. EirGenix had revenue of 363.62M in the quarter ending December 31, 2025, with 23.41% growth.
Revenue
1.01B
Revenue Growth
-0.38%
P/S Ratio
14.35
Revenue / Employee
1.01M
Employees
1,000
Market Cap
14.42B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.01B | -3.80M | -0.38% |
| Dec 31, 2024 | 1.01B | -13.69M | -1.34% |
| Dec 31, 2023 | 1.02B | -458.36M | -30.95% |
| Dec 31, 2022 | 1.48B | -216.34M | -12.75% |
| Dec 31, 2021 | 1.70B | 625.52M | 58.36% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| TaiMed Biologics | 611.35M |
| Polaris Group | 40.60M |
| Locus Cell | 12.74M |
| Medigen Vaccine Biologics | 613.17M |
| Ever Supreme Bio Technology | 1.02B |
| AP Biosciences | 32.25M |
| Tanvex BioPharma | 400.97M |
| CHO Pharma | 1.43M |